NASH - February 2021

NASH - February 2021

Target RWE announced results on weight loss from an ongoing NASH longitudinal observational study

02 Feb 2021

Target RWE

  • TARGET-NASH is a 5-year longitudinal observational study of patients being managed for NAFL or NASH in usual clinical practice, within academic and community real-world practices
  • The study (published in Clinical Gastroenterology & Hepatology) analyzed 2,019 patients enrolled in the TARGET-NASH cohort in US over a median follow-up of 39 months
  • Results:
    • 32% of patients had weight reduction of 5% or more
    • Median time to initial weight loss was shorter in patients who were obesity class 2/3
    • Only 25% of patients maintained 5% or more weight loss
    • Among those with initial weight loss, 21% regained weight back to baseline during follow-up, and 59% of those patients did so within the first year of weight loss

At 39 months follow-up, only 25% of patients maintained the weight reduction of >/= 5%

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share

CI Scientists Remarks:

  • In Jan’19, Target RWE announced a long-term strategic alliance with Novartis for TARGET-NASH
  • The TARGET model of Target RWE is responsible for generating real world evidence about the natural history of the disease, current treatment paradigm, and patient outcomes, for its stakeholders, which include pharmaceutical companies, KOLs, regulatory agencies, and patient advocacy groups
  • It also enables the stakeholders to answer critical strategic and planning questions and provides access to a repository for patient reported outcomes

– Akshat Gulati, CI Scientists

For full story click here

Home